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ABSTRACT  Moraxella catarrhalis  respiratory infection was clinically studied. Subjects were 
32 patients with M.  catarrhalis  respiratory infection who were treated in Kawasaki Hospital, 
Kawasaki Medical School from January 2006 to December 2010. The clinical features of 
these cases have been retrospectively reviewed. The results showed that: (1) There was not 
only acute exacerbation of chronic lower respiratory tract infection (in 11) and community-
acquired pneumonia (in 18), but also hospital-acquired pneumonia (in 3); (2) There was frequent 
occurrence in elderly male patients with chronic respiratory disease or malignant tumor as an 
underlying disease; (3) Most patients were mild or moderate, and rarely severe; (4) Although 
there are many bacteria resistant to ABPC and ST, sensitivity remains against third- and fourth- 
generation cephem, carbapenem, and new quinolone; (5) Mixed infections with S. pneumoniae , 
or H. influenzae  were observed; (6) Prognosis is good when the third- or fourth-generation 
cephem, carbapenem, or new quinolone is administered (clinical efficacy rate 100 percent, and 
eradication rate 100 percent).
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INTRODUCTION
   Moraxella catarrhlis is important as the causative 
organism for acute exacerbation of chronic lower 
respiratory tract infection, and is also said to 
have high frequency as the causative organism 
of community-acquired pneumonia following 
Streptococcus pneumoniae and Haemophilus 
influenzae1,2,3,4). This study aimed at clarifying 
the clinical features of M. catarrhlis respiratory 
infection.
SUBJECTS AND METHODS
Subjects
   The subjects were 32 patients with M. catarrhalis 
respiratory infection who were treated at Kawasaki 
Hospital, Kawasaki Medical School from January 
2006 to December 2010.
   M. catarrhalis respiratory infection is defined as 
respiratory infection with sputum culture containing 
107 /ml or more of M. catarrhalis.
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Methods
   Type of respiratory infection, such as acute 
exacerbation of chronic lower respiratory tract 
infection, community-acquired pneumonia, and 
hospital-acquired pneumonia5), severity, underlying 
disease, sensitivity against various types of 
antibacterial drugs, simultaneously detected bacteria, 
treatment, clinical efficacy, and bacteriological 
efficacy of patients were retrospectively studied.
RESULTS
Cases
   Thirty-two patients with M. catarrhalis respiratory 
infection were examined. The patients included 
acute exacerbation of chronic lower respiratory 
tract infection in 11 patients, community-acquired 
pneumonia in 18, and hospital-acquired pneumonia 
in 3.
Acute exacerbation of chronic lower respiratory 
tract infection (Table 1)
   There were 4 males and 7 females aged 53 to 89 
years.
   Underlying disease included chronic obstructive 
pulmonary disease (COPD) in 7 patients, bronchial 
asthma in 2, old pulmonary tuberculosis in 1, and 
bronchiectasis in 1. 
   With regard to sensitivity against various types 
of antibacterial drugs, 8 (73 percent) of 11 strains 
were resistant to ampicillin (ABPC), 6 (55 percent) 
of 11 strains were resistant to ST, 2 (18 percent) of 
11 strains were resistant to cefazolin (CEZ), and 1 
(9 percent) of 11 strains was resistant to cefotiam 
(CTM), while all the strains were sensitive to 
cefotaxime (CTX), imipenem / cilastin (IPM/CS), 
minocycline (MINO), and levofloxacin (LVFX). 
One patient developed mixed infection with 
penicillin-intermittent Streptococcus pneumoniae 
(PISP).
   As t reatment ,  levofloxacin (LVFX) was 
administered to 5 patients, cefditoren (CDR) to 
2 and cefotiam (CTM), cefepim (CFPN), and 
panipenem / betamipron (PAPM / BP) to 1 , 
respectively. 
   Clinical efficacy was good in all patients, and all 
strains were eradicated. 
Community-acquired pneumonia (Table 2)
   There were 13 males and 5 females aged 58 to 91 
years.
   Underlying disease included COPD in 5 patients, 
bronchial asthma in 2, lung cancer in 2, diabetes 
Table 1.　Clinical features of patients with  Moraxella catarrhalis infection
(exacerbations of chronic lower respiratory tract infection)
Patients Age(years) Gender
Underlying
 diseases Severity
Susceptibility M. catarrhalis to antibiotics Concurrent
isolated
bacteria
Treatment Clinicalefficacy
Bacteriological
efficacyABPC CEZ CTM CTX IPM/CS MINO LVFX ST
1 53 Ｆ COPD － Ⓡ S S S S S S S (-) CDTR Good Eradicated
2 65 M COPD － Ⓘ S S S S S S S (-) LVFX Good Eradicated
3 65 F COPD － Ⓘ S S S S S S S (-) LVFX Good Eradicated
4 71 F Bronchialasthma － S S S S S S S Ⓡ (-) CDTR Good Eradicated
5 71 Ｆ COPD － Ⓘ Ⓘ S S S S S Ⓡ (-) LVFX Good Eradicated
6 72 M Oldtuberculosis － Ⓡ S S S S S S S (-) LVFX Good Eradicated
7 73 F COPD － S S S S S S S S (-) PAPM/BP Good Eradicated
8 73 F Bronchiectasis － S S S S S S S Ⓘ (-) CFPM Good Eradicated
9 83 F Bronchialasthma － Ⓡ S S S S S S Ⓡ (-) CTM Good Eradicated
10 87 M COPD － Ⓡ S S S S S S Ⓡ (-) CPFX Good Eradicated
11 89 M COPD － Ⓡ Ⓡ Ⓡ S S S S Ⓘ PISP LVFX Good Eradicated
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mellitus in 2, and chronic renal failure (undergoing 
dialysis), mitral regurgitation, hypertension, and old 
pulmonary tuberculosis in 1, respectively. 
   Severity was mild in 1 patient, moderate in 15 and 
severe in 2. 
   With regard to sensitivity to various types of 
antibacterial drugs, 14 (78 percent) of 18 strains 
were resistant to ABPC, 6 (33 percent) of 18 
strains were resistant to ST, and 1 (6 percent) of 
18 strains was resistant to CEZ, CTM, and MINO, 
respectively, while all the strains were sensitive to 
CTX, IPM/CS, and LVFX. Two patients developed 
mixed infection with Haemophilus influenzae. One 
patient developed mixed infection with penicillin-
sensitibe S.pneumoniae (PSSP). 
   As t reatment ,  meropenem (MEPM) was 
administered to 5 patients, LVFX to 3, cefpirome 
(CPR) and CPFX to 2,subactam / ampicillin (SBT 
/ ABPC), cefotiam (CTM), CFPM, cefozopran 
(CZOP), IPM/CS, and garenofloxacin (GRNX) to 1, 
respectively.  
   Clinical efficacy was good in all patients, and all 
strains were eradicated. 
Hospital-acquired pneumonia (Table 3)
   There were 2 males and 1 female aged 65 to 89 
years.
   Underlying disease included idiopathic interstitial 
pneumonias, malignant melanoma , and gastric 
cancer, respectively. 
Table 2.　Clinical features of patients with  Moraxella catarrhalis infection (community-acquired pneumonia)
Patients Age(years) Gender
Underlying
diseases Severity
Susceptibility M. catarrhalis to antibiotics Concurrent
isolated
bacteria
Treatment Clinicalefficacy
Bacteriological
efficacyABPC CEZ CTM CTX IPM/CS MINO LVFX ST
1 58 M Bronchial asthma mild Ⓡ S S S S S S S (-) SBT/ABPC Good Eradicated
2 73 M Chronic renal failure moderate Ⓘ S S S S S S Ⓘ (-) CFPM Good Eradicated
3 73 M Mitral regurgitation moderate Ⓡ Ⓡ Ⓘ S S Ⓘ S S (-) GRNX Good Eradicated
4 74 M COPD moderate Ⓡ S S S S S S Ⓘ (-) LVFX Good Eradicated
5 75 M Hypertension moderate Ⓡ S S S S S S Ⓘ (-) LVFX Good Eradicated
6 77 F Gastric ca moderate S S S S S S S S (-) MEPM Good Eradicated
7 77 M COPD severe Ⓡ S S S S S S S PSSP CZOP Good Eradicated
8 80 M COPD severe Ⓡ S S S S S S S (-) MEPM Good Eradicated
9 82 M COPD moderate S S S S S S S S (-) IPM/CS Good Eradicated
10 82 Ｍ Lung ca moderate Ⓡ S S S S S S Ⓘ (-) CPR Good Eradicated
11 83 Ｆ Bronchial asthma moderate S S S S S S S S H. influenzae MEPM Good Eradicated
12 83 Ｍ Old tuberculosis moderate Ⓡ S S S S S S S (-) LVFX Good Eradicated
13 84 Ｍ Diabetes mellitus moderate Ⓡ S S S S S S S (-) CPEX Good Eradicated
14 84 Ｆ Parkinson's dis moderate Ⓡ S S S S S S Ⓡ (-) CPR Good Eradicated
15 87 Ｆ COPD moderate Ⓡ S S S S S S Ⓘ (-) CPFX Good Eradicated
16 88 M Lung ca moderate Ⓘ S S S S S S S H. influenzae CTM Good Eradicated
17 90 M Diabetes mellitus moderate S S S S S S S S (-) MEPM Good Eradicated
18 91 Ｆ Darmatomyositis moderate Ⓘ S S S S S S S (-) MEPM Good Eradicated
Table 3.　Clinical features of patients with Moraxella catarrhalis infection (hospital-acquired pneumonia)
Patients Age(years) Gender
Underlying
diseases Severity
Susceptibility M. catarrhalis to antibiotics Concurrent
isolated
bacteria
Treatment Clinical efficacy
Bacteriological
efficacyABPC CEZ CTM CTX IPM/CS MINO LVFX ST
1 65 Ｍ IIPs mild Ⓡ S S S S S S S (-) CAZ Good Eradicated
2 80 Ｍ Malignantmelanoma mild Ⓡ S S S S S S Ⓘ (-) CAZ Good Eradicated
3 89 Ｆ Gastric ca mild Ⓡ S S S S S S Ⓘ (-) MEPM Good Eradicated
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   Severity was mild in all patients.  
  With regard to sensitivity to various type of 
antibacterial drug, 3 (100 percent) of 3 strains were 
resistant to ABPC, 2 (67 percent) of 3 strains were 
resistant to ST, while all the strains were sensitive to 
CEZ, CTM, CTX, IPM/CS, MINO, and LVFX. 
   As treatment, ceftazidime (CAZ) was administered 
to 2 patients, and MEPM to 1.
   Clinical efficacy was good in all patients, and all 
strains were eradicated. 
DISCUSSION
   M. catarrhlis is said to hold an important position 
as the causative organism for acute exacerbation 
of chronic lower respiratory tract infection and 
community-acquired pneumonia. This study 
revealed that acute exacerbation of chronic lower 
respiratory tract infection occurred in 11 patients, 
while community-acquired pneumonia occurred 
in 18 patients and hospital-acquired pneumonia 
occurred in 3 patients, thus the number of patients 
with pneumonia was larger than that with acute 
exacerbation of chronic lower respiratory tract 
infection. This suggests that M. catarrhlis is also the 
causative organism of hospital-acquired pneumonia. 
Verducin et al.6) also reported that it is not only 
the causative organism for respiratory infection 
which occurs out of hospital but also the causative 
organism of respiratory infection which occurs in 
hospital.
   Acute exacerbation of chronic lower respiratory 
tract infection occurred in 4 males and 7 females 
aged 53  to  89  years ,  communi ty-acquired 
pneumonia occurred in 13 males and 5 females aged 
58 to 91 years, and hospital-acquired pneumonia 
occurred in 2 males and 1 female aged 65 to 89 
years, showing M. catarrhalis respiratory infection 
occurred most frequently in elderly male patients. 
Babay7) and Verducin et al.6) also reported that 
elderly males develop it with the greatest frequency. 
   All 32 patients had underlying disease. In not only 
acute exacerbation of chronic lower respiratory 
tract infection, but also in community-acquired 
pneumonia and hospital-acquired pneumonia, most 
are respiratory diseases such as COPD, or bronchial 
asthma, and malignant tumor (lung cancer, gastric 
cancer, and malignant melanoma) was observed in 
3 patients. Verducin et al.6) reported that chronic 
respiratory disease was observed the most frequently 
as the underlying disease, which is consistent with 
our findings. Nagatake et al.1) reported that with 
the exception of malignant tumor, cerebrovascular 
diseases was frequently observed. It is presumed 
that when cases of hospital-acquired pneumonia are 
observed, cerebrovascular diseases increase as the 
underlying disease, as was observed by Nagatake. 
   Therefore, it is suggested that M. catarrhlis 
respiratory infection occurs in elderly males with 
chronic respiratory disease or malignant tumor as 
the underlying disease.
   With regard to severity, community-acquired 
pneumonia was mild in 1 ,  moderate in 15 , 
and severe in 2 patients, and hospital-acquired 
pneumonia was mild in 3 patients. This suggests 
that M. catarrhlis pneumonia occurs mildly or 
moderately and less frequently severely. Past 
studies6,8) have also reported frequent mild or 
moderate severity, and the invasiveness was weaker 
than S.pneumoniae. However, sepsis has been 
reported to occur rarely in immunocompromised 
patients9,10,11,). 
   With regard to sensitivity to various types of 
antibacterial drugs, 25 (78 percent) of 32 strains 
were resistant to ABPC, 14 (44 percent) of 32 
strains were resistant to ST, 3 (9 percent) of 32 
strains were resistant to CEZ, and 2 (6 percent) of 
32 strains was resistant to CTM, and 1 (3 percent) 
of 32 strains were resistant to MINO. It was 
concluded that third- and fourth-generation cephem, 
carbapenem, and new quinolone should be selected 
for M. catarrhlis pneumonia or respiratory infection 
rather than ABPC, ST, first- and second-generation 
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cephem, or MINO. Several studies6,7,8,12,13) have 
reported that many bacteria are resistant to ABPC 
or first-generation cephem antibiotics, and cephem 
of third-generation or later, carbapenem, and that 
new quinolone are effective in treatment, which is 
consistent with our findings. 
   Four (13 percent) of 32 patients had mixed 
infection, 2 were infected with S. pneumoniae 
(PSSP 1 and PISP 1) and 2 were infected with H. 
influenzae. Although the number of patients is 
small, attention should be paid to the fact that mixed 
infection with the 3 major causative organisms was 
found. In the literature, complications are seen not 
only with S.pneumniae or H.influezae1,8) but also 
with Mycoplasma pneumoniae14). 
   As treatment, new quinolone were administered to 
13 patients, including LVFX to 8, CPFX to 3, and 
GRNX to 2. Third- and fourth-generation cephem 
were administered to 9 patients, including CDTR 
to 2, CFPM to 2, CPR to 2, CAZ to 2, and CZOP 
to 2, carbapenem were administered to 8 patients, 
including MEPM to 6, PAPM / BP to 1, and IPM 
/ CS to 1. These choices were considered valid in 
terms of the guidelines2,4,5) regarding respiratory 
infection as well as in terms of sensitivity. As 
a result, clinical efficacy was 100 percent and 
eradication rate was 100 percent. Therefore M. 
catarrhalis respiratory infection may have a good 
prognosis when treated appropriately. 
 It is concluded as follows: (1) M. catarrhalis 
respiratory infection which we have experienced 
included not only acute exacerbation of chronic 
lower respiratory tract infection and community-
acquired pneumonia, but also hospital-acquired 
pneumonia; (2) It occurs in elderly male patients 
with chronic respiratory disease or malignant tumor 
as an underlying disease; (3) Many cases are mild 
or moderate, and severe cases are rare; (4) Although 
there are many bacteria resistant to ABPC and ST, 
sensitivity remains to third- and fourth-generation 
cephem, carbapenem, and new quinolone; (5) Mixed 
infections with S. pneumoniae, or H. influenzae 
were observed; (6) Prognosis is good when the 
third- or fourth-generation cephem, carbapenem, or 
new quinolone are administered (clinical efficacy 
rate 100 percent, and eradication rate 100 percent). 
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